Citadel Advisors
GLMD icon

Citadel Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Citadel Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$26 – 14651
2023
Q3 		$26 Buy
+4
New +$53 ﹤0.01% 14192
2021
Q3 		– Sell
-76
Closed -$41K – 14094
2021
Q2 		$41K Sell
76
-6
-7% -$3.26K ﹤0.01% 13406
2021
Q1 		$51K Buy
+82
New +$56.7K ﹤0.01% 12892
2019
Q1 		– Sell
-71
Closed -$87K – 9499
2018
Q4 		$87K Buy
+71
New +$124K ﹤0.01% 8305

Other funds holding GLMD

Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's GLMD Position: Q1 2026 in Review

Citadel Advisors reduced its Galmed Pharmaceuticals (GLMD) stake by 70% in Q1 2026, selling an estimated $18.1K and leaving 11,382 shares worth $5.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12812.

Citadel Advisors first reported a position in GLMD in Q2 2021 and has held it in 11 quarters since. The position peaked at $120K in Q2 2021. 16 funds tracked by Wall St. Rank hold GLMD as of Q1 2026.

  • Citadel Advisors held 11,382 shares of Galmed Pharmaceuticals worth $5.5K as of Q1 2026.
  • Citadel Advisors sold 26,795 Galmed Pharmaceuticals shares in Q1 2026, an estimated $18.1K.
  • Galmed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12812 holding.
  • Citadel Advisors first reported a position in Galmed Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • Citadel Advisors's Galmed Pharmaceuticals position peaked at $120K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.